INDV
Indivior·NASDAQ
--
--(--)
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 1
Consensus Rating "Strong Buy"
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INDV
Indivior Pharmaceuticals, Inc.
A global specialty pharmaceutical company and a global leader in the treatment of opioid dependence
10710 Midlothian Turnpike, Suite 125, North Chesterfield , VA 23235
--
Indivior Pharmaceuticals, Inc., was incorporated as a public limited company under the laws of England and Wales on September 26, 2014 and re-registered in Delaware on January 26, 2026. Indivior is committed to improving the lives of patients through the development of drugs to treat opioid use disorder (OUD). Based on its existing OUD therapeutic portfolio, Indivior has a portfolio of product candidates designed to further expand its business in this field.
Company Financials
EPS
INDV has released its 2025 Q3 earnings. EPS was reported at 0.72, versus the expected 0.39, beating expectations. The chart below visualizes how INDV has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INDV has released its 2025 Q3 earnings report, with revenue of 314.00M, reflecting a YoY change of 2.28%, and net profit of 42.00M, showing a YoY change of 90.91%. The Sankey diagram below clearly presents INDV's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
